Overview

• Experts in Mexico report that average survival for many patients has more than doubled to over 10 years, driven by earlier detection and modern regimens.
• New data presented in Mexico describe CAR-T as a one-time intravenous therapy with a 97% response rate and potential control lasting up to 17 years, though it is not approved in the country and can cost $500,000 to $1 million per dose.
• Civil society marked September 5 by illuminating key Mexico City monuments in burgundy to raise awareness and press for equitable access to treatments.
• Mexico records roughly 2,400 new myeloma cases annually, with an average diagnosis age near 58 and many patients presenting at advanced stages after months of nonspecific symptoms.
• Access gaps persist, including limited availability of autologous transplants—an estimated 18,000 people need one and only about 10% receive it—underscoring calls for better infrastructure and testing.